INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Cancer is a large group of diseases that can start in almost any organ or tissue of the body. Rectal wall is made up of layers of tissue. Cancer begins in the innermost layer that comes in touch with food. Dostarlimab is a humanized monoclonal antibody that is developed for the treatment of various cancers. Brand name of Dostarlimab is jemperli. Dosage of Dostarlimab in adults include Dose 1 through 4 of jemperli is 500mg every 3weeks. Common side effects of Dostarlimab may include abnormal liver function tests, nausea, diarrhoea, constipation, low white blood cell counts, anaemia, or feeling weak or tired. Dostarlimab belong to class of drugs called anti-programmed cell death-1 (PD-1) monoclonal antibodies, immune checkpoint inhibitors, programmed death-ligand 1 (PD-L1) blocking antibodies. This drug was initially tried in treating uterine cancer and it was found to be effective. The recent study by the memorial Sloan Kettering cancer centre, New York, is the first clinical investigation that shown its effectiveness against rectal cancer. In the trial patients had stage II or III cancer and drug was given every three weeks for six months. The trial shown dramatic results that there are no apparent signs of tumour after at least follow-up for six months in rectal cancer patients. Locally advanced rectal cancer is usually managed by neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum. Recent evidence suggests that use of neoadjuvant therapy in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin followed by chemotherapy and then surgery.In recent clinical trial Dostarlimab is used for rectal cancer and it shown prominent result. But longer follow-up is needed to assess the drug drug whether disease cautious to be uncontrolled or whether the drug is safe.
"Dostralimab in Rectal Cancer: A Comprehensive Review", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.7, Issue 8, page no.233-238, August-2022, Available :http://www.ijnrd.org/papers/IJNRD2208026.pdf
Downloads:
000118759
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn